Peter KH Lin

CFO and Director of Operation and Administration
Skingenix, Inc.
Ontario, CA

(IBEAR 23)

Peter serves as the Chief Financial Officer and the Director of Operations and Administration for a start-up pharmaceutical company. The company is conducting nonclinical and clinical studies for submission to the U.S. FDA under Investigational New Drug (IND) application for topical prescription drug. Peter also serves as the head of a family office where he incubates and manages various venture projects. Prior to joining the pharma start-up, Peter was the principal of Solarium Capital, a boutique private equity investment fund, where he analyzed and executed acquisitions and equity investment in organizations and projects in cross functional industries such as technology, food and beverage, and real estates. The portfolio companies generated 20x return in 5 years. Right after the IBEAR program, Peter joined WesCorp as investment research manager. He managed investment credit research team of a $32 Billion fixed income portfolio, one of the largest structured credit investment portfolio in the world. The team conducted credit research and analysis of fixed income securities on U.S. and global structured finance securities such as Residential and Commercial Mortgage-Backed Securities (MBS), Asset-Backed Securities (ABS), Collaterized Debt Obligations (CDO), various esoteric ABS, and Corporate Debt Securities. Peter earned his bachelor’s degree in Business Administration from University of California Berkeley, his master degree in Information Systems from Claremont Graduate University, and his International Business Education and Research (IBEAR) MBA from USC. Peter is also a Chartered Alternative Investment Analyst (CAIA) charter holder.